GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Ultragenyx Pharmaceutical Inc (NAS:RARE) » Definitions » 3-Month Share Buyback Ratio

RARE (Ultragenyx Pharmaceutical) 3-Month Share Buyback Ratio : -0.20% (As of Dec. 2024 )


View and export this data going back to 2014. Start your Free Trial

What is Ultragenyx Pharmaceutical 3-Month Share Buyback Ratio?

Shares Outstanding (EOP) are shares that have been authorized, issued, and purchased by investors and are held by them.

3-Month Share Buyback Ratio measures the proportion of a company's outstanding shares repurchased over the past three months, calculated as the percentage change in shares outstanding from the previous quarter to the current quarter. A positive ratio may indicates share buybacks over the period, while a zero or negative ratio suggests no buybacks or potential share issuance. Ultragenyx Pharmaceutical's current 3-Month Share Buyback Ratio was -0.20%.

Competitive Comparison of Ultragenyx Pharmaceutical's 3-Month Share Buyback Ratio

For the Biotechnology subindustry, Ultragenyx Pharmaceutical's 3-Month Share Buyback Ratio, along with its competitors' market caps and 3-Month Share Buyback Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Ultragenyx Pharmaceutical's 3-Month Share Buyback Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Ultragenyx Pharmaceutical's 3-Month Share Buyback Ratio distribution charts can be found below:

* The bar in red indicates where Ultragenyx Pharmaceutical's 3-Month Share Buyback Ratio falls into.


;
;

Ultragenyx Pharmaceutical 3-Month Share Buyback Ratio Calculation

Ultragenyx Pharmaceutical's 3-Month Share Buyback Ratio for the quarter that ended in Dec. 2024 is calculated as

3-Month Share Buyback Ratio=(Shares Outstanding (EOP) (Sep. 2024 ) - Shares Outstanding (EOP) (Dec. 2024 )) / Shares Outstanding (EOP) (Sep. 2024 )
=(92.304 - 92.484) / 92.304
=-0.20%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Ultragenyx Pharmaceutical  (NAS:RARE) 3-Month Share Buyback Ratio Explanation

A positive ratio may indicates share buybacks over the period, while a zero or negative ratio suggests no buybacks or potential share issuance.

Be Aware

Investors usually like share buybacks. But as pointed by Warren Buffett, only if a company buys back shares at the prices below the stock's intrinsic value, it rewards remaining shareholders. If a company buys its overvalued stocks back, it destroys shareholder value.

Ultragenyx Pharmaceutical 3-Month Share Buyback Ratio Related Terms

Ultragenyx Pharmaceutical Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Ultragenyx Pharmaceutical Inc (NAS:RARE) » Definitions » 3-Month Share Buyback Ratio
Comparable Companies
ZLAB ACLX SLNO RNA SWTX CRSP AKRO PTCT RYTM SRRK VRTX ASX:CSL REGN XKRX:207940 XBRU:ARGX ALNY XBRU:UCB ONC BNTX XKRX:068270
Traded in Other Exchanges
0LIF:UK UP0:Germany
Address
60 Leveroni Court, Novato, CA, USA, 94949
Website
https://www.ultragenyx.com
Ultragenyx Pharmaceutical Inc is a USA-based biopharmaceutical company. It identifies, acquires, develops, and commercializes novel products for the treatment of serious rare and ultra-rare diseases, with a focus on serious, debilitating genetic diseases. The company's medicine portfolio includes Crysvita, Dojolvi and Mepsevii. Crysvita is indicated for the treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients 1 year of age and older. Mepsevii is indicated in pediatric and adult patients for the treatment of Mucopolysaccharidosis VII.
Executives
Howard Horn officer: Chief Financial Officer C/O VIR BIOTECHNOLOGY, INC., 499 ILLINOIS STREET, SUITE 500, SAN FRANCISCO CA 94158
Eric Crombez officer: EVP and Chief Medical Officer C/O ULTRAGENYX PHARMACEUTICAL INC., 60 LEVERONI COURT, NOVATO CA 94949
Theodore Alan Huizenga officer: Controller and PAO C/O ULTRAGENYX PHARMACEUTICAL INC., 60 LEVERONI COURT, NOVATO CA 94949
Thomas Richard Kassberg officer: CBO & Senior Vice President C/O ULTRAGENYX PHARMACEUTICAL INC., 60 LEVERONI COURT, NOVATO CA 94949
John Richard Pinion officer: See Remarks C/O ULTRAGENYX PHARMACEUTICAL INC., 60 LEVERONI COURT, NOVATO CA 94949
Erik Harris officer: EVP & Chief Commercial Officer 60 LEVERONI COURT, NOVATO CA 94949
Karah Herdman Parschauer officer: EVP and General Counsel 60 LEVERONI COURT, NOVATO CA 94949
Emil D Kakkis director, 10 percent owner, officer: President & CEO C/O ULTRAGENYX PHARMACEUTICAL INC., 60 LEVERONI COURT, NOVATO CA 94949
Sanders Corazon (corsee) D. director C/O MOLECULAR TEMPLATES, INC., 9301 AMBERGLEN BLVD, SUITE 100, AUSTIN VI 78729
Matthew K Fust director C/O ULTRAGENYX PHARMACEUTICAL INC., 60 LEVERONI COURT, NOVATO CA 94949
Dennis Karl Huang officer: SVP and Chief Tech Ops Officer C/O ULTRAGENYX PHARMACEUTICAL INC., 60 LEVERONI COURT, NOVATO CA 94949
Camille L Bedrosian officer: EVP and Chief Medical Officer C/O ULTRAGENYX PHARMACEUTICAL INC., 60 LEVERONI COURT, NOVATO CA 94949
Mardi Dier officer: CFO & Executive Vice President C/O ACELYRIN, INC., 4149 LIBERTY CANYON RD., AGOURA HILLS CA 91301
Amrit Ray director 60 LEVERONI COURT, NOVATO CA 94949
William Aliski director C/O ULTRAGENYX PHARMACEUTICAL INC., 60 LEVERONI COURT, NOVATO CA 94949